Veritable’s Xeris Biopharma Holdings XERS Stock Holding History

Veritable’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-32,174	Closed	-$50K	–	909
2022 Q2	$50K	Buy	+32,174	New	+$67.9K	﹤0.01%	876

Other funds holding XERS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Veritable's XERS Position: Q3 2022 in Review

Veritable sold out of Xeris Biopharma Holdings (XERS) in Q3 2022, closing a stake of 32,174 shares — an estimated $50K sold.

Veritable first reported a position in XERS in Q2 2022 and held it in 1 quarter. The position peaked at $50K in Q2 2022. 101 funds tracked by Wall St. Rank hold XERS as of Q3 2022.

Veritable reported no remaining Xeris Biopharma Holdings position as of Q3 2022 after selling out during the quarter.
Veritable sold 32,174 Xeris Biopharma Holdings shares in Q3 2022, an estimated $50K.
Veritable first reported a position in Xeris Biopharma Holdings in Q2 2022 and held it in 1 quarter.
Veritable's Xeris Biopharma Holdings position peaked at $50K in Q2 2022.
101 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2022.

Based on Veritable's 13F filing for Q3 2022, filed 14 Nov 2022.